Heart FailureASQNCT04024943
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
An observational study of Heart Failure, run by Medtronic at 115 sites in 9 countries.
Trial summary
The purpose of this Post-Approval Study (PAS) is to evaluate the long-term performance of the Model 4798 Left Ventricular (LV) lead in a real-world patient population. Patients will be followed for the duration of the PAS. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Heart Failure
- What is being tested?
- Quadripolar LV Lead
- Type of treatment
- Medical device
- How many people
- 1,092 participants
- Where
- 115 sitesin 9 countries
- Study dates
- 21 Aug 2017to Jan 2028
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population includes patients that are or will be implanted with a Model 4798 lead and a Medtronic CRT device.
Who may be able to join
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive or be treated with a Model 4798 lead and a Medtronic CRT device
- Patient within 30 days of therapy received at the time of their initial PSR platform enrollment
Who cannot join
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Trial locations and contacts
115 sites in 9 countries.
115 sites in 9 countries
United States72 sites
Summa Center for Clinical Trials-Northeast Ohio Cardiovascular Specialists
Akron, Ohio, 44304-1473
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701-1943
Presbyterian Heart Group
Albuquerque, New Mexico, 87106-4921
Alaska Heart
Anchorage, Alaska, 99508-4673
Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, 78705-1852
MedStar Health Research Institute
Baltimore, Maryland, 21237-3958
Our Lady of the Lake Office of Research
Baton Rouge, Louisiana, 70808
South Shore University Hospital
Bay Shore, New York, 11706
St. Luke's University Health Network
Bethlehem, Pennsylvania, 18015-1155
Massachusetts General Hospital
Boston, Massachusetts, 02114-2621
Brigham & Women's Hospital (Boston, MA)
Boston, Massachusetts, 02115-6110
Southwest EP
Chandler, Arizona, 85295-1680
Chula Vista Cardiac Center
Chula Vista, California, 91910
The Christ Hospital Health Network
Cincinnati, Ohio, 45219
University of Cincinnati
Cincinnati, Ohio, 45267-0542
Clearwater Cardiovascular Consultants
Clearwater, Florida, 33756-3356
Cleveland Clinic
Cleveland, Ohio, 44195
Colorado Springs Cardiology
Colorado Springs, Colorado, 80907
Missouri Cardiovascular Specialists
Columbia, Missouri, 65201-8023
University Hospital of Missouri
Columbia, Missouri, 65212
Geisinger Medical Center
Danville, Pennsylvania, 17822
Denver Heart
Denver, Colorado, 80220-3918
Duke University Medical Center (DUMC)
Durham, North Carolina, 27705
Saint Elizabeth Healthcare
Edgewood, Kentucky, 41017
UPMC Heart and Vascular Institute at UPMC Hamot
Erie, Pennsylvania, 16507-1579
Deaconess Specialty Physicians
Evansville, Indiana, 47710
Heart Center of North Texas
Fort Worth, Texas, 761014
Consultants in Cardiology
Fort Worth, Texas, 76104-2821
Hartford Hospital
Hartford, Connecticut, 06102
Heart Rhythm Solutions
Hollywood, Florida, 33021
Huntington Hospital
Huntington, New York, 11743
Baptist Health
Jacksonville, Florida, 32207
Cardiology Associates of Northeast Arkansas
Jonesboro, Arkansas, 72410-4163
Kansas University Medical Center
Kansas City, Kansas, 66160-8500
Saint Lukes Health System
Kansas City, Missouri, 64111-5934
Colorado Heart and Vascular
Lakewood, Colorado, 80228
Sparrow Clinical Research Institute
Lansing, Michigan, 48912
Saint Vincent Heart Clinic Arkansas
Little Rock, Arkansas, 72205-6202
Norton Heart Specialists
Louisville, Kentucky, 40205-3373
North Shore University Hospital
Manhasset, New York, 11030
UP Health System - Marquette
Marquette, Michigan, 49855-2705
Aurora Cardiovascular Services
Milwaukee, Wisconsin, 53215
Northern Westchester Hospital
Mount Kisco, New York, 10549
Saint Thomas Research Institute
Nashville, Tennessee, 37205-2018
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-8802
Yale New Haven Hospital
New Haven, Connecticut, 06520-8017
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, 10021
New York-Presbyterian Hospital/Columbia University Medical Center
New York, New York, 10032
Lenox Hill Hospital
New York, New York, 10075
Monmouth Cardiology Associates
Ocean City, New Jersey, 07712-4762
Nebraska Medicine
Omaha, Nebraska, 68105
Cardiovascular Institute of Northwest Florida
Panama City, Florida, 32405
Hudson Valley Heart Center
Poughkeepsie, New York, 12601-3923
WakeMed Health & Hospitals
Raleigh, North Carolina, 27610
North Memorial Heart and Vascular Institute
Robbinsdale, Minnesota, 55422
Mayo Clinic
Rochester, Minnesota, 55905
Heart & Vascular Institute of Florida
Safety Harbor, Florida, 34695-6604
Tidal Health Peninsula Regional
Salisbury, Maryland, 21804-6938
San Diego Arrhythmia Associates
San Diego, California, 92103
Heart Rhythm Consultants P.A. (Sarasota Memorial Research)
Sarasota, Florida, 34233
Associates in Cardiology PA
Silver Spring, Maryland, 20910-1265
Kootenai Heart Clinics Northwest
Spokane, Washington, 99204-2352
Washington University
St Louis, Missouri, 63110-1010
Staten Island University Hospital
Staten Island, New York, 10305-3436
EP Heart
The Woodlands, Texas, 77384
COR Healthcare
Torrance, California, 90505
Cardiovascular Consultants Medical Group (Van Nuys)
Van Nuys, California, 91405-3646
Cardiology Associates Medical Group
Ventura, California, 93003
Iowa Heart Center
West Des Moines, Iowa, 50266
Geisinger Wyoming Valley Medical Center
Wilkes-Barre, Pennsylvania, 18711
Michigan Heart
Ypsilanti, Michigan, 48197-8633
France13 sites
Clinique Rhône Durance
Avignon, 84082
Centre Hospitalier de la Côte Basque
Bayonne, 64109
CHRU Brest - Hôpital de la Cavale Blanche
Brest, 29609
Générale de Santé - Hôpital Privé Saint Martin
Caen, 14000
CHU de Caen - Hôpital Côte de Nacre - Centre Esquirol
Caen, 14033
CHU de Clermont Ferrand
Clermont-Ferrand, 63003
CHU de Dijon - Hospital Le Bocage
Dijon, 21079
CHRU La Rochelle
La Rochelle, 17019
Hopital prive Clairval - Ramsay Sante
Marseille, 13009
Nouvelles Cliniques Nantaises
Nantes
Centre hospitalier de la région d'Annecy
Pringy, 74374
Centre Hospitalier Universitaire Saint Étienne - Hôpital Nord
Saint-Priest-en-Jarez, 42270
Capio - Clinique du Tonkin
Villeurbanne, 69100
Spain8 sites
Hospital Universitario da Coruna
A Coruña, 15006
Hospital Universitario Virgen de las Nieves
Granada, 18014
Hospital Universitario Clínico San Cecilio
Granada
Hospital Universitario 12 de Octubre
Madrid, 28041
Complejo Universitario de Salamanca
Salamanca, 37007
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, 38010
Complejo Hospitalario Universitario de Santiago de Compostela
Santiago de Compostela, 15706
Hospital Clínico Universitario de Valladolid
Valladolid, 47006
United Kingdom7 sites
University Hospitals of Birmingham NHS Foundation Trust - Queen Elizabeth Hospital
Birmingham
Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust - Blackpool Victoria Hospital
Blackpool
Liverpool Heart and Chest Hospital NHS Foundation Trust
Liverpool
Imperial College Healthcare NHS Trust - Hammersmith Hospital
London
Central Manchester University Hospitals NHS - Manchester Royal Infirmary
Manchester
The James Cook University Hospital - South Tees Hospitals NHS
Middlesbrough
Sheffield Vascular Institute, Sheffield Teaching Hospitals NHS - Northern General
Sheffield
Italy6 sites
Policlinico Sant' Orsola - Malpighi
Bologna, 40138
Azienda Sanitaria Provinciale di Cosenza "Ospedale di Castrovillari"
Castrovillari, 87012
Ospedale "Vito Fazzi" Lecce
Lecce, 73100
Azienda Ospedaliera Ospedale Niguarda Ca Granda
Milan, 20162
Presidio Ospedaliero Centrale - SS. Annunziata
Taranto, 74024
Azienda ospedaleria Santa Maria della Misericordia di Udine
Udine
Portugal4 sites
Hospital da Senhora da Oliveira - Guimarães
Guimarães, 4835-044
Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, EPE
Lisbon, 1649-035
Centro Hospitalar Universitário de São João
Porto, 4200-319
Hospital Distrital de Santarém
Santarém, 2000-177
Greece2 sites
Hygeia Hospital
Athens, 15123
Athens Medical Center
Marousi, 15125
Switzerland2 sites
Hôpitaux Universitaires de Genève
Geneva, 1205
Cardiopark Zurich
Zurich, 8027
Slovakia1 site
Národný ústav srdcových a cievnych chorôb, a.s. (NUSCH, a.s.)
Bratislava
About this study
The purpose of this Post-Approval Study (PAS) is to evaluate the long-term performance of the Model 4798 Left Ventricular (LV) lead in a real-world patient population. Patients will be followed for the duration of the PAS. This study is required by FDA as a condition of approval of the Model 4798 LV lead and is integrated within the Product Surveillance Registry (PSR).
Read the detailed description
The Attain Stability Quad (ASQ) PAS is a multi-center, single arm, prospective observational study. However, in the US, retrospective enrollments from participants in the IDE study (IDE #G170020) are allowed.
- Conditions
- Heart Failure
- Being tested
- Quadripolar LV Lead
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quadripolar LV LeadDevice
Also called Medtronic CRT-P, Medtronic CRT-D
The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients without a lead- related event at 5 years post-implant
To demonstrate that the complication-free probability is greater than 92.5% at five years post-implant for Attain Stability Quad LV leads.
Measured: 5 years
Secondary outcomes (2)
Number of lead-related adverse device effects
The secondary objectives are descriptive in nature and are intended to gain additional information about the safety and performance of the Product:
- To summarize all Attain Stability Quad lead-related ADEs
Measured: 5 years
Number of explanted leads that have been returned
The secondary objectives are descriptive in nature and are intended to gain additional information about the safety and performance of the Product:
- To summarize analysis results from explanted and returned Attain Stability Quad leads
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2019
- Study start21 Aug 2017
- Primary completionJul 2027 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by MedtronicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,092 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Medtronic
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04024943
- Sponsor's protocol ID
- Attain Stability Quad PAS
- Acronym
- ASQ
- Status last verified
- Jan 2026
- First submitted
- 24 Jun 2019
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Yee R, Love CJ, Kaiser DW, Birgersdotter-Green U, Cha YM, Singh JP, Liu S, Zhang Y, Chung ES. Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms. J Card Fail. 2025 May;31(5):824-832. doi: 10.1016/j.cardfail.2024.11.011. Epub 2024 Dec 16.
PubMed 39694452
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personalized Therapy Study - Attain Stability Quad Post-Approval Study
- ClinicalTrials.gov ID
- NCT04024943
- Acronym / sponsor ID
- ASQ / Attain Stability Quad PAS
- Conditions
- Heart Failure
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,092 participants (actual)
- Lead sponsor
- MedtronicIndustry (pharma, biotech, devices)
- Study start
- 21 Aug 2017 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 18 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this Post-Approval Study (PAS) is to evaluate the long-term performance of the Model 4798 Left Ventricular (LV) lead in a real-world patient population. Patients will be followed for the duration of the PAS. This study is required by FDA as a condition of approval of the Model 4798 LV lead and is integrated within the Product Surveillance Registry (PSR).
Detailed description
The Attain Stability Quad (ASQ) PAS is a multi-center, single arm, prospective observational study. However, in the US, retrospective enrollments from participants in the IDE study (IDE #G170020) are allowed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population includes patients that are or will be implanted with a Model 4798 lead and a Medtronic CRT device.
Key inclusion criteria (3 listed)
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive or be treated with a Model 4798 lead and a Medtronic CRT device
- Patient within 30 days of therapy received at the time of their initial PSR platform enrollment
Key exclusion criteria (3 listed)
- Patient who is, or is expected to be inaccessible for follow-up
- Patient with exclusion criteria required by local law
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quadripolar LV LeadAlso: Medtronic CRT-P, Medtronic CRT-DThe Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location. | Device | – |
Primary outcome
Percentage of patients without a lead- related event at 5 years post-implant
Time frame: 5 years
To demonstrate that the complication-free probability is greater than 92.5% at five years post-implant for Attain Stability Quad LV leads.
2 secondary outcomes
Number of lead-related adverse device effects
Time frame: 5 years
Number of explanted leads that have been returned
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Derived from this study: PubMed 39694452Yee R, Love CJ, Kaiser DW, Birgersdotter-Green U, Cha YM, Singh JP, Liu S, Zhang Y, Chung ES. Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms. J Card Fail. 2025 May;31(5):824-832. doi: 10.1016/j.cardfail.2024.11.011. Epub 2024 Dec 16.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
115 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by Medtronic at 115 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 115 sites in United States, France, Spain, United Kingdom, Italy and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients without a lead- related event at 5 years post-implant (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04024943, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.